The combination of baricitinib, an anti-inflammatory drug, and remdesivir, an antiviral, reduced time to recovery for people hospitalized with COVID-19, according to clinical trial results published in the New England Journal of Medicine. The study was supported by the National Institute of Allergy and Infectious Diseases (NIAID), part of the National Institutes of Health.
The National Institutes of Health will provide support to institutions to recruit diverse groups or “cohorts” of early-stage research faculty and prepare them to thrive as NIH-funded researchers.
Testing will still be a critical tool against COVID-19, even as vaccines are deployed against the disease, the head of the World Health Organization (WHO) said on Friday during his regular briefing on the crisis.
Using a life support machine to replicate the functions of the heart and lungs significantly improved the survival of people who suffered from out-of-hospital cardiac arrest, according to a new study published today in The Lancet(link is external).
Long-term SARS-CoV-2 shedding was observed from the upper respiratory tract of a female immunocompromised patient with chronic lymphocytic leukemia and acquired hypogammaglobulinemia.
Two experts from Harvard T.H. Chan School of Public Health explored the implications of the 2020 election for the future of U.S. health policy in a special report in the New England Journal of Medicine
Because COVID-19 has overstretched the resources needed to fund essential services like education and health in Africa, the increased continental debt burden and limited inflows of aid and foreign development investment, there is pressure, more than ever to raise revenue locally.
